Document is current
Any future updates will be listed below
-
Authors
Mian, Hira
Martin, Thomas G.
Pond, Gregory R. https://orcid.org/0000-0003-1033-0882
Asoori, Sireesha
Popat, Rakesh
Kastritis, Efstathios
Martinez-Lopez, Joaquin https://orcid.org/0000-0001-7908-0063
Abdallah, Nadine https://orcid.org/0000-0001-9195-1589
Chhabra, Saurabh
Parrondo, Ricardo https://orcid.org/0000-0002-9314-9933
Ailawadhi, Sikander https://orcid.org/0000-0002-8377-8111
Dimopoulos, Meletios A. https://orcid.org/0000-0001-8990-3254
Yong, Kwee https://orcid.org/0000-0002-6487-276X
Durie, Brian GM.
Usmani, Saad Z. https://orcid.org/0000-0002-5484-8731
Lin, Yi https://orcid.org/0000-0002-1556-6416
Tan, Carlyn Rose https://orcid.org/0000-0001-7922-2594
- License Information
-
More Information
Article History
Received: 5 December 2024
Revised: 29 December 2024
Accepted: 24 February 2025
First Online: 20 March 2025
Ethics approval and consent to participate
: Informed consent was obtained from all participants and this this study received approval from the Institutional Review Boards of the respective participating institutions including the Hamilton Integrated Research Ethics Board (# 16667) in Hamilton, Ontario, Canada. All methods were performed in accordance with the relevant guidelines and regulations.
: - Mian: Research funding (Janssen, Pfizer), Honoraria/Advisory Board Janssen/J&J, GSK, Sanofi, Pfizer, Takeda, AbbVie. - Martin: Research funding (Sanofi, Janssen, Amgen, BMS); consultant – GSK, Roche, Pfizer. - Pond: Honoraria: Takeda, Consultancy: Astra-Zeneca, Merck, Profound Medical and Traferox, Equity Holding: Roche. - Asoori: None. - Popat: Research funding: Pfizer, GSK; consultant: Roche, GSK; honoraria: J&J, AbbVie, BMS, Pfizer, GSK. - Kastritis: honoraria from Janssen/J&J, GSK, Sanofi, Pfizer; institutional research funding Janssen/J&J, GSK, Pfizer. - Martinez-Lopez:Research funding: BMS, Pfizer and Astellas Consulting: Amgen, BMS, Gilead, GSK, Johnson and Johnson, Oncopeptides, Menarini, Sanofi, Roche and Novartis. - Chhabra: honoraria from Sanofi, Sobi, Ascentage Pharma; institutional research funding from Abbvie, C4 therapeutics, Carsgen, Takeda, Johnson & Johnson. - Abdallah: None. -Parrondo: Research funding (GSK, Bristol Myers Squibb foundation); Consultant (Astra Zeneca, Sanofi Aventis). - Ailawadhi: Research funding to institution: GSK, BMS, Pharmacyclics, Amgen, Sanofi, Janssen, Cellectar, Xencor, Abbvie, Ascentage. Consultancy: GSK, Sanofi, BMS, Takeda, Beigene, Regeneron, Pharmacyclics, Amgen, Janssen. - Dimopoulos: Honoraria: Amgen, Takeda, Janssen-Cilag, Bristol-Myers Squibb, Beigene, Sanofi; Consulting or Advisory Role: Amgen, Janssen-Cilag, Takeda, Bristol-Myers Squibb, Beigene,Sanofi. - Yong: Consultancy / ad board for Sanofi, Pfizer, GSK, Amgen; Research funding: Sanofi, BMS. - Durie: None. - Usmani: Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda. Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio. - Lin: Consultancy: Janssen, Legend, Celgene, Sanofi, Bristo-Myers, Regeneron, Genentech, Research Funding: Janssen, Celgene, Bristol-Myers, Advisory Boards: Nexlmmune, Caribou, Pfizer. - Tan: received research funding from Janssen, Sanofi, and Takeda; consultant (Janssen, Sanofi).
